One of the last major, late-stage attempt at stopping Alzheimer’s disease (AD) using a BACE inhibitor has ended up on the trash pile with so many others.

Earlier this year, Biogen and partner Eisai canned the remaining phase 3 trial of aducanumab, their first BACE asset aimed at AD, effectively killing off the program after it turned out to be a dud.